Stanford Diabetes Work-In-Progress Seminar Series

 

Participants: Members of Participating Stanford Research Groups.

Meeting Time: Every Friday, 12:00-1:00 pm.

Meeting Location: Beckman 302, Developmental Biology Library.

Each Friday, a different thematic group presents:

1st Friday: Pancreas and Islet Biology

2nd Friday: Bioengineering and Behavioral Sciences

3rd Friday: Metabolism and Signaling

4th Friday: Immunology and Islet Transplantation

 

Organizers:

Justin Annes MD PhD, Assistant Professor, Department of Medicine, Division of Endocrinology; Leader of the Enrichment Program for SDRC

Meeting Forum:

Each session, held monthly, includes two speakers who provide a 20-25 minute discussion of their ongoing diabetes-related research. Presentation topics range from clinical research to basic science investigation, promoting a knowledge and collaboration between these spheres. The presentation format encourages questions and discussion both during and after each presentation. Presentations primarily focus on un-published work and as these meetings are intended to build new collaborations, share new insights (particularly new technologic innovations and how they might be applied) and facilitate new ideas/ research directions. Presenters and attendees include everyone from professors to undergraduate students. Thus this venue also aligns with our center’s training mission. Typical attendance is ~30-40 individuals per session. Snacks and drinks are provided to facilitate informal socializing and discussion following the presentations.

 

Up-Coming Meetings

October 19th:

Vivek Bhalla: “Role of Esm-1 as a Kidney-enriched Inhibitor of Leukocyte Infiltration and Albuminuria in Diabetic Nephropathy”

Baohui Xu (Dalman Lab): “TBA”

Past Meetings

October 12th: Cancelled due to ISPAD 2018 conference overlap

October 5th: Katja Pekrun(Kay lab):“DirectedEvolution of AAV for Islet Targeting”
Andrew Lipchik(Snyder lab): “Antibody-mediated inhibition of mitochondrial respiration as a predictor of insulin resistance”

September 28th: Jon Piganelli (Associate Professor, Children’s Hospital of Pittsburgh): Adaptive but Not Terminal UPR Induces Human β cell Immunogenicity: First Step in the Progression of β cell Destruction”

September 21st: Jiehan Li (Ingelsson lab): Genetic screening in adipocytes: combining CRISPR perturbations and single-cell RNA sequencing

Francois Haddad: Precision Initiatives in Diabetic Cardiomyopathy

September 14th: Peter Robinson: A new method for detecting antibody biomarkers in autoimmune diabetes

Molly Tanenbaum: Human factors as a pathway to improving diabetes care

September 7th: Gozde Durmus (Thakor lab): Levitating Pancreatic Tissues for Islet Transplantation

Kimberly Tsui (Bassik lab): Uncovering genetic modulators of Antibody-Drug Conjugate toxicity using CRISPR/Cas9 Screens

June 15th: Christopher Gardner: Recruitment Strategies for Trials – Lessons Learned, Resource Being Created

May 18th: Dr. Mohsen Fathzadeh (Knowles): The human lipodystrophy-like gene FAM13A affects fat distribution and function in mice
  
Dr. Katrin Svensson: Isthmin-1 is a hormone that regulates peripheral glucose homeostasis

May 11th: Dr. Eric Appel - Innovations in Insulin Formulation by Supramolecular Design

April 6th: Kyle Loh - Prospects for using human embryonic stem cells to treat diabetes: replacing the immune system or generating pancreatic progenitors?"

Hannah Moeller (Annes Lab) - Discovering Pathways Promoting Beta-Cell Identity and Function

March 30th: Dr. Eyal Dassau - The Artificial Pancreas and Connected Diabetes Care: A Patient Centric Design

March 23rd: Dr. Garrison Fathman - A novel approach to rejuvenate endogenous Treg function in the treatment of autoimmune diseases; can one drug treat all these diseases?

Discussion session led by the leaders

March 16th: Dr. Rick Kraemer - Cholesterol trafficking for steroidogenesis

Dr. Maurizio Morri (Ingelsson lab) – CRISPR-based high-throughput screening and validation of putative candidate genes for insulin resistance

March 9th: Event Cancelled

March 2nd: Event Cancelled

February 23rd: Dr. Jeffrey Liu (Roncarolo lab) - Engineering Tr1 cells to induce immune tolerance

Dr. Nadine Nagy - 4-methylumbelliferyl Glucuronide Inhibits Hyaluronan Synthesis and Promotes Foxp3+ Regulatory T-cell Induction

February 16th: Zahra Bahrami-Nejad (Teruel lab) - A core component of mature adipocytes enforces cell identity by mediating adipocyte differentiation

Dr. Terry Unterman - Regulatory Networks in Diabetes: Integrated Regulation of Hepatic Glucose and Lipid Metabolism by FoxO Proteins

February 9th: Jason Tsai (Bertozzi lab): Sensitive and multiplex quantification of anti-Islet cell antibodies for Type 1 Diabetes diagnostics and risk assessments

Dr. Anisha Patel: Examining Policies to Promote Access to Free Water in Schools as an Alternative to Sugar Sweetened Beverages

February 2nd: Monte Winslow: Genome Engineering in the Mouse Pancreas/Marina Basina: Managing Type 2 Diabetes: Where are we in 2018?

January 26th: Dr. Everett Meyer (Defining disease associated invariant NKT in human type 1 diabetes)/Dr. Paul Bollyky (IL-2 delivery and immune modulation in type 1 diabetes)

January 12th: Tom Soh (Technology for continuously measuring specific biomolecules in vivo)/Korey Hood (Science of Behavior: Opportunities to Optimize Diabetes Outcomes)

January 10, 2018: Invited guest speaker - Danny Chou, PhD Assistant Professor-University of Utah "Toward Optimal Insulin Action and Performance for People with Diabetes"